Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicentre double-blind randomized placebo-controlled phase 3 study of tezepelumab in severe uncontrolled asthma
2018-002501-53Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in severe asthma and asthma comparing Tezepelumab 210 mg with Placebo (2 arms). Primary endpoint: Exposure adjusted incidence rates of AEs/SAEs. Started Dec 2018; status: completed.
02
Drugs
03
Conditions
severe asthmaasthma
Beyond the preview
Go deeper on 2018-002501-53.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002501-53.